The Diagnostic Chain That Expanded Into a Loss
Twice the centres, half the profit. Where did the model break?
The Prompt
Your client is a pathology-lab chain that grew from 40 to 85 collection centres in 18 months, all feeding two central processing labs. Revenue grew 60%, but EBITDA halved. The board approved the expansion expecting operating leverage — instead margins collapsed. Why, and what now?
Opening exchange
Expansion cases usually break in one of three places: the new units underperform, the new units differ structurally from the old, or the centre cannot absorb the added load. So: are the 45 new centres like-for-like with the original 40 — same cities, same customer mix, same test mix?
Good question — no. The original 40 are walk-in retail centres in two metros. Most new centres are in smaller cities, and many were opened to service B2B contracts: hospitals, clinics, and insurance wellness programmes.
One clarifying question collapses half the hypothesis space. This is what "structure your clarifications" means.
So the expansion changed the business mix, not just the footprint. B2B pathology typically prices 30–50% below retail. I'll structure around segment economics — old retail vs new B2B — plus the central-lab and logistics costs that scale with distance.
Structure & Hypothesis
Analysis & Data
Numbers: retail realizes ₹520/test at 38% contribution. B2B realizes ₹290/test at 12% contribution after logistics. B2B is now 55% of volume. Also, B2B receivables run at 90+ days, and the central labs added a night shift at a 25% wage premium to hold turnaround times.
Let me bridge it. The blended contribution fell from 38% to roughly 23% just from mix. The night-shift premium and transit re-tests push another few points down. And the 90-day receivables mean we're funding hospitals' working capital — at 60% revenue growth, that's a cash squeeze on top of the margin squeeze.
Connects P&L to working capital unprompted — interviewers consistently reward this.
The CEO says: "B2B is strategic — it fills the labs and the brand needs the hospital relationships." How do you respond?
Partly true: B2B volume above the fixed-cost line is fine even at thin margins — but only if it's priced above its variable cost including logistics and penalties, paid on time, and scheduled into off-peak lab hours. Today it fails all three tests in the small-city centres. I'd keep B2B, but re-cut it: re-price or exit contracts below variable-cost-plus, enforce 45-day terms, and batch B2B processing into daytime slack.
Recommendation
Recommend to the board
- Re-price or exit B2B contracts whose realization sits below variable cost + logistics + penalty risk; target 20%+ contribution on renewals.
- Move B2B batch processing to daytime slack capacity; reserve the night shift for retail TAT promises only.
- Tighten B2B terms to 45 days with interest clauses; stop being the banker to hospital chains.
- For the next expansion wave, add a third regional processing lab — distance costs, not demand, are the binding constraint beyond ~300 km.
Key Takeaway
What this case teaches
"Operating leverage" only materializes when new volume resembles old volume. When expansion changes the mix — segment, geography, payment terms — model the new cohort's economics on its own, and check the cash cycle, not just the P&L.